Ubs Asset Management Americas Inc Cyclerion Therapeutics, Inc. Transaction History

Ubs Asset Management Americas Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$0.47 - $1.29 $4,770 - $13,092	-10,149 Closed	0 $0
Q4 2020 Mar 01, 2021	SELL	$2.25 - $7.12 $32,550 - $103,005	-14,467 Reduced 58.77%	10,149 $31,000
Q2 2020 Aug 14, 2020	SELL	$2.37 - $7.14 $105,078 - $316,566	-44,337 Reduced 64.3%	24,616 $145,000
Q1 2020 May 15, 2020	BUY	$2.46 - $5.84 $64,461 - $153,031	26,204 Added 61.3%	68,953 $182,000
Q4 2019 Feb 14, 2020	SELL	$1.8 - $13.43 $1.8 Million - $13.4 Million	-997,640 Reduced 95.89%	42,749 $116,000
Q3 2019 Nov 14, 2019	BUY	$8.12 - $14.54 $1.91 Million - $3.41 Million	234,835 Added 29.15%	1,040,389 $12.6 Million
Q2 2019 Aug 15, 2019	BUY	$9.6 - $22.85 $7.73 Million - $18.4 Million	805,554 New	805,554 $0

293K

Ticker CYCN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,479,800
Market Cap $141M
Description
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of...

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

Stay updated on Ubs Asset Management Americas Inc with notifications on news.